Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tiragolumab by Genentech USA for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Metastatic Renal Cell Carcinoma. According to...
Tiragolumab by Genentech USA for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase III for Esophageal Squamous Cell Carcinoma (ESCC). According...
Tiragolumab by Genentech USA for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Tiragolumab by Genentech USA for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase III for Metastatic Hepatocellular Carcinoma (HCC). According to...
Tiragolumab by Genentech USA for Solid Tumor: Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Tiragolumab by Genentech USA for Laryngeal Cancer: Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase...
Tiragolumab by Genentech USA for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Recurrent Head And Neck Squamous Cell...
Tiragolumab by Genentech USA for Hypopharyngeal Cancer: Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase...
Tiragolumab by Genentech USA for Oropharyngeal Cancer: Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase...
Tiragolumab by Genentech USA for Rectal Cancer: Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Rectal Cancer. According to GlobalData, Phase...
Tiragolumab by Genentech USA for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Tiragolumab by Genentech USA for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase III for Metastatic Hepatocellular Carcinoma (HCC). According to...
Tiragolumab by Genentech USA for Solid Tumor: Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Roche's Tiragolumab?
Tiragolumab is a monoclonal antibody commercialized by Roche, with a leading Phase III program in Esophageal Squamous Cell Carcinoma (ESCC)....